Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-06-09
2011-12-06
Andres, Janet (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C514S328000
Reexamination Certificate
active
08071780
ABSTRACT:
The present invention provides novel piperidine derivatives of formula (I),wherein R represents a substituted benzyl group, which are useful as inhibitors of glucosylceramide synthase (GCS). The compounds of the Invention are useful for treating various glycolipid storage diseases, such as Gaucher's disease, Sandhoff's disease, Tay-Schs disease, Fabry disease, and GM1 gangliosidosis; glycolipid accumulation disorders, such as Niemann-Pick disease, mucopolysaccharidoses, mucolipidosis type IV and α-mannosidosis; various cancers that involve abnormal glycolipid synthesis; and various infectious diseases that involve cell surface glycolipids as receptors for the infectious organisms or for their toxins; as well as a variety of other disorders involving glycolipid synthesis, including neuronal disorders, inflammatory diseases, obesity, and the like.
REFERENCES:
patent: 4407809 (1983-10-01), Junge et al.
patent: 4639436 (1987-01-01), Junge et al.
patent: 4639463 (1987-01-01), Rosner et al.
patent: 5003072 (1991-03-01), Partis et al.
patent: 5051407 (1991-09-01), Boshagen et al.
patent: 5276120 (1994-01-01), Wong et al.
patent: 5798366 (1998-08-01), Platt et al.
patent: 6046214 (2000-04-01), Kristiansen et al.
patent: 6225325 (2001-05-01), Jacob
patent: 6426198 (2002-07-01), Carstea et al.
patent: 6495570 (2002-12-01), Jacob et al.
patent: 6683076 (2004-01-01), Walkley et al.
patent: 7256005 (2007-08-01), Zitzmann et al.
patent: 2001/0044453 (2001-11-01), Jacob et al.
patent: 2004/0019082 (2004-01-01), Van der Spoel et al.
patent: 2006/0058349 (2006-03-01), Ali et al.
patent: 2006/0074107 (2006-04-01), Butters et al.
patent: 2006/0111400 (2006-05-01), Ali et al.
patent: 2007/0112028 (2007-05-01), Orchard et al.
patent: 2007/0259918 (2007-11-01), Orchard
patent: 2008/0234324 (2008-09-01), Scopes et al.
patent: 3024901 (1982-01-01), None
patent: 0491041 (1992-06-01), None
patent: 0 536 402 (1993-04-01), None
patent: 0 698 012 (1994-11-01), None
patent: 698012 (1997-01-01), None
patent: 698102 (2006-03-01), None
patent: 1-02/306962 (1990-12-01), None
patent: H02-306962 (1990-12-01), None
patent: 3-24057 (1991-02-01), None
patent: WO 92/00277 (1992-01-01), None
patent: WO 94/26714 (1994-11-01), None
patent: WO 98/02161 (1998-01-01), None
patent: WO 98/30219 (1998-07-01), None
patent: WO 99/24401 (1999-05-01), None
patent: WO 00/33843 (2000-06-01), None
patent: WO 00/56334 (2000-09-01), None
patent: WO 00/62780 (2000-10-01), None
patent: WO 01/10429 (2001-02-01), None
patent: WO 02/055489 (2002-07-01), None
patent: WO 02/055498 (2002-07-01), None
patent: WO 2004/007453 (2004-01-01), None
patent: WO 2004/007454 (2004-01-01), None
patent: WO 2004/111001 (2004-12-01), None
patent: WO 2004/111002 (2004-12-01), None
patent: WO 2005/068426 (2005-07-01), None
Giulio Alessandri, et al., “Angiogenic and Angiostatic Microenvironment in Tumors,” Anct Onco. (1997), 36(4), pp. 383-387.
Anthony Lucci, et al., “Glucosylceramide: a Marker for Multiple-Drug Resistant Cancers,” Anticancer Res. (1998), 18(1 B), pp. 475-480.
Peter De Man, et al., “Bacterial adherence as a virulence factor in urinary tract infection,” APMIS (1990), 98(12), pp. 1053-1060.
Km Nicholson, et al., “Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase,” Br. J. Cancer (1999), 81(3), pp. 423-430.
Gunnar C. Hansson, et al., “A novel approach to the study of glycolipid receptors for viruses,” FEBS Lett. (1984), 170(1), pp. 15-18.
Victor Jimenez-Lucho, et al., “Cryptococcus neoformans, Candida albicans, and Other Fungi Bind Specifically to the Glycosphingolipid Lactosylceramide (Galβ1-4Glcβ1-1Cer), a Possible Adhesion Receptor for Yeasts,” Infect. Immun. (1990), 58(7), pp. 2085-2090.
Yaakov Lavie, et al., “Agents that Reverse Multidrug Resistance, Tamoxifen, Verapamil, and Cyclosporin A, Block Glycosphingolipid Metabolism by Inhibiting Ceramide Glycosylation in Human Cancer Cells,” J. Biol. Chem. (1997) 272(3), pp. 1682-1687.
Yong-Yu Liu, et al., “Uncoupling Ceramide Glycosylation of Transfection of Glucosylceramide Synthase Antisense Reverses Adriamycin Resistance,” J. Biol. Chem. (2000), 275(10), pp. 7138-7143.
Ruixiang Li, et al., “Cellular Gangliosides Promote Growth Factor-inducted Proliferation of Fibroblasts,” J. Biol. Chem. (2000), 275(44), pp. 34213-34223.
Ivan Z. Zador, et al., “A Role for Glycosphingolipid Accumulation in the Renal Hypertrophy of Streptozotocin-induced Diabetes Mellitus,” Clin. Invest. (1993), 91(3), pp. 797-903.
Akira Abe, et al., “Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation,” J. Clin. Invest. (2000), 105(11), pp. 1563-1571.
Robert Mckallip, et al., “Tumor Gangliosides Inhibit the Tumor-Specific Immune Response,” J. Immuno. (1999), 163(7), pp. 3718-3726.
Majlis Svensson, et al., “Carbohydrate Receptor Depletion as an Antimicrobial Strategy for Prevention of Urinary Tract Infection,” J. Infect. Dis. (2001), suppl. 70-73, p. 183.
Subroto Chatterjee, et al., “Role of lactosylceramide and MAP kinase in the proliferation of proximal tubular cells in human polycystic kidney disease,” J. Lipid. Res. (1996), 37(6), pp. 1334-1344.
Timothy Cox, et al., “Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis,” Lancet (2000), 355(9214), pp. 1481-1485.
N.V. Prokazova, et al., “Gangliosides and Atherosclerosis,” Lipids (1994), 29(1), pp. 1-5.
Kazuko Handa, et al., “Analysis of Glycolipid-Dependent Cell Adhesion Based on Carbohydrate-Carbohydrate Interaction,” Methods Enzymol. (2000), 312, pp. 447-458.
Clifford A. Lingwood, et al., “Analysis of Interactions between Glycosphingolipids and Microbial Toxins,” Methods Enzymol. (2000), 312, pp. 459-473.
Abderrahim Merzak, et al., “Gangliosides Modulate Proliferation, Migration, and Invasiveness of Human Brain Tumor Cells in Vitro,” Mol. Chem. Neuropathol. (1995), 24(2-3), pp. 121-135.
Kai Simons et al., “Functional rafts in cell membranes,” Nature (1997), 387(6633), pp. 569-572.
Praveen Tyle, “Iontophoretic Devices for Drug Delivery,” Pharmaceutical Research (1986), 3(6), p. 318.
Linda A. Goodman, et al., “Ectopic dendrites occur only on cortical pyramidal cells containing elevated GM2 ganglioside in α-mannosidosis,” Proc. Natl. Acad. Sci. USA (1991), 88(24), pp. 11330-11334.
Chii-Shiaring Chen, et al., “Abnormal transport along the lysosomal pathway in Mucolipidosis, type IV disease,” Proc. Natl. Acad. Sci. USA (1998), 95(11), pp. 6373-6378.
Mylvaganam Jeyakumar, et al., “Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin,” Proc. Natl. Acad. Sci. USA (1999), 96(11), pp. 6388-6393.
Protective Groups in Organic Chemistry, T.W. Greene and P.G.M. Wuts, (Wiley-Interscience, New York, 2nd edition) (1991).
Frances M. Platt, et al., “Prevention of Lysosomal Storage in Tay-Sachs Mice Treated with N-Butyldeoxynojirimycin,” Science (1997), 276(5311), pp. 428-431.
Milton Alter, “GM1, Ganglioside for Acute Ischemic Stroke,” Alter, Ann. NY Acad. Sci. (1998), 845, pp. 391-401.
Lin-P'Ing Choo-Smith et al., “Acceleration of Amyloid Fibril Formation by Specific Binding of Aβ-(1-40) Peptide to Ganglioside-containing Membrane Vesicles,” Biol. Chem. (1997), 272, pp. 22987-22990.
Fowler, P.A. et al., Synthesis and activity towards yeast α-glucosidase of 1,5-dideoxy-1,5-imino-L-iditol (1-deoxy-L-idonojirimycin), Carbohydr. Res. (1993), 246, pp. 377-381.
Fred H. Geisler, “Clinical Trials of Pharmacotherapy for Spinal Cord Injury,” NY Acad. Sci. (1998), 845, pp. 374-381.
Memon, R.A. et al.,“Regulation of Glycosphingolipid Metabolism in Liver during the Acute Phase Respons
Actelion Pharmaceuticals Ltd.
Andres Janet
Hoxie & Associates LLC
Mabry John
LandOfFree
2-Hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-Hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-Hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4264247